{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T12:45:39Z","timestamp":1782737139539,"version":"3.54.5"},"reference-count":26,"publisher":"American Medical Association (AMA)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Cardiol"],"published-print":{"date-parts":[[2025,10,1]]},"abstract":"<jats:sec><jats:title>Importance<\/jats:title><jats:p>Given their kidney actions, it is important to evaluate the efficacy and safety of mineralocorticoid receptor antagonists when combined with other diuretics and whether they have a so-called diuretic-sparing effect in patients with heart failure (HF).<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>To examine the efficacy and tolerability of finerenone related to background diuretic treatment in patients with heart failure with mildly reduced or preserved ejection fraction (HFmrEF\/HFpEF).<\/jats:p><\/jats:sec><jats:sec><jats:title>Design, Setting, and Participants<\/jats:title><jats:p>This study is a prespecified secondary analysis of the FINEARTS-HF (Finerenone Trial to Investigate Efficacy and Safety Superior to Placebo in Patients With Heart Failure) randomized clinical trial, which was conducted across 653 sites in 37 countries among adults aged 40 years and older with HFmrEF\/HFpEF, who were randomized between September 2020 and January 2023. Data analysis was conducted from December 1, 2024, to January 30, 2025.<\/jats:p><\/jats:sec><jats:sec><jats:title>Intervention<\/jats:title><jats:p>Finerenone (titrated to 20 mg or 40 mg) or placebo.<\/jats:p><\/jats:sec><jats:sec><jats:title>Main Outcomes and Measures<\/jats:title><jats:p>The primary outcome was the composite of total HF events and cardiovascular death. Outcomes were compared between finerenone and placebo according to the following baseline diuretic categories: only a nonloop diuretic (thiazide or thiazide-like); loop diuretic (\u226440 mg vs &amp;amp;gt;40 mg furosemide-equivalent dose); and combined nonloop and loop diuretic use.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Among 5438 patients, 2496 (45.9%) were female, and mean (SD) age was 72.1 (9.6) years. A total of 684 patients (12.6%) were receiving a nonloop diuretic,  3040 (55.9%) less than or equal to 40 mg furosemide equivalent, 1145 (21.1%) 40 mg or greater furosemide equivalent, and 569 (10.5%) both nonloop and loop diuretics. Compared with placebo, finerenone reduced the risk of the primary end point across all diuretic subgroups: rate ratios were 0.84 (95% CI, 0.47-1.51), 0.86 (95% CI, 0.72-1.02), 0.98 (95% CI, 0.78-1.24), and 0.54 (95% CI, 0.35-0.83) for patients in the nonloop, 40 mg or less loop, more than 40 mg loop, and combined nonloop and loop categories, respectively (<jats:italic>P<\/jats:italic> for interaction\u2009=\u2009.18). Compared with placebo, finerenone reduced loop diuretic dose and dose intensification, but not loop diuretic initiation. Safety was consistent across diuretic categories.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions and Relevance<\/jats:title><jats:p>In this secondary analysis of the FINEARTS-HF randomized clinical trial, the efficacy and safety of finerenone were consistent across all diuretic subgroups. Compared with placebo, finerenone reduced the use of diuretics in patients with HFmrEF\/HFpEF; however, finerenone did not reduce the initiation of new loop diuretic in participants not receiving a loop diuretic at baseline.<\/jats:p><\/jats:sec><jats:sec><jats:title>Trial Registration<\/jats:title><jats:p>ClinicalTrials.gov Identifier: <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.clinicaltrials.gov\/study\/NCT04435626?cond=NCT04435626&amp;amp;amp;rank=1\">NCT04435626<\/jats:ext-link><\/jats:p><\/jats:sec>","DOI":"10.1001\/jamacardio.2025.2551","type":"journal-article","created":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T15:00:44Z","timestamp":1755097244000},"page":"979","source":"Crossref","is-referenced-by-count":10,"title":["Efficacy and Tolerability of Finerenone According to the Use and Dosage of Diuretics"],"prefix":"10.1001","volume":"10","author":[{"given":"Misato","family":"Chimura","sequence":"first","affiliation":[{"name":"British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, United Kingdom"},{"name":"Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, Suita, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pardeep S.","family":"Jhund","sequence":"additional","affiliation":[{"name":"British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alasdair D.","family":"Henderson","sequence":"additional","affiliation":[{"name":"British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingming","family":"Yang","sequence":"additional","affiliation":[{"name":"British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian L.","family":"Claggett","sequence":"additional","affiliation":[{"name":"Cardiovascular Division, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akshay S.","family":"Desai","sequence":"additional","affiliation":[{"name":"Cardiovascular Division, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Rohwedder","sequence":"additional","affiliation":[{"name":"Bayer AG, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Lage","sequence":"additional","affiliation":[{"name":"Bayer AG, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Scalise","sequence":"additional","affiliation":[{"name":"Bayer AG, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Mueller","sequence":"additional","affiliation":[{"name":"Bayer AG, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morten","family":"Schou","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Herlev-Gentofte University Hospital, Hellerup, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn S. P.","family":"Lam","sequence":"additional","affiliation":[{"name":"National Heart Centre Singapore and Duke-National University of Singapore, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Senni","sequence":"additional","affiliation":[{"name":"Papa Giovanni XXIII Hospital, University of Milano-Bicocca, Bergamo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriaan A.","family":"Voors","sequence":"additional","affiliation":[{"name":"University Medical Center Groningen, Groningen, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faiez","family":"Zannad","sequence":"additional","affiliation":[{"name":"Inserm Clinical Investigation Centre, Universit\u00e9 de Lorraine, CHU, Nancy, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertram","family":"Pitt","sequence":"additional","affiliation":[{"name":"School of Medicine, University of Michigan, Ann Arbor"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muthiah","family":"Vaduganathan","sequence":"additional","affiliation":[{"name":"Cardiovascular Division, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott D.","family":"Solomon","sequence":"additional","affiliation":[{"name":"Cardiovascular Division, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J. V.","family":"McMurray","sequence":"additional","affiliation":[{"name":"British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"17","key":"hoi250039r1","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1001\/archinte.1994.00420170045004","article-title":"Diuretic treatment for the sodium retention of congestive heart failure.","volume":"154","author":"Cody","year":"1994","journal-title":"Arch Intern Med"},{"issue":"18","key":"hoi250039r2","doi-asserted-by":"publisher","first-page":"e895","DOI":"10.1161\/CIR.0000000000001063","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines.","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"issue":"1","key":"hoi250039r3","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1002\/ejhf.2333","article-title":"2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure of the European Society of Cardiology (ESC). with the special contribution of the Heart Failure Association (HFA) of the ESC.","volume":"24","author":"McDonagh","year":"2022","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"hoi250039r4","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1136\/hrt.57.1.17","article-title":"Untreated heart failure: clinical and neuroendocrine effects of introducing diuretics.","volume":"57","author":"Bayliss","year":"1987","journal-title":"Br Heart J"},{"issue":"2","key":"hoi250039r5","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.ahj.2003.08.012","article-title":"Relationship between heart failure treatment and development of worsening renal function among hospitalized patients.","volume":"147","author":"Butler","year":"2004","journal-title":"Am Heart J"},{"issue":"12","key":"hoi250039r6","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1016\/j.amjcard.2005.12.072","article-title":"Relation of loop diuretic dose to mortality in advanced heart failure.","volume":"97","author":"Eshaghian","year":"2006","journal-title":"Am J Cardiol"},{"issue":"10","key":"hoi250039r7","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1016\/j.ejheart.2007.07.011","article-title":"Relation between dose of loop diuretics and outcomes in a heart failure population: results of the ESCAPE trial.","volume":"9","author":"Hasselblad","year":"2007","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"hoi250039r8","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1159\/000164149","article-title":"Impact of intravenous loop diuretics on outcomes of patients hospitalized with acute decompensated heart failure: insights from the ADHERE registry.","volume":"113","author":"Peacock","year":"2009","journal-title":"Cardiology"},{"issue":"9","key":"hoi250039r9","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1002\/ejhf.1917","article-title":"Diuretic and renal effects of spironolactone and heart failure hospitalizations: a TOPCAT Americas analysis.","volume":"22","author":"Kalogeropoulos","year":"2020","journal-title":"Eur J Heart Fail"},{"issue":"2","key":"hoi250039r10","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.ahj.2010.05.032","article-title":"Diuretic dose and long-term outcomes in elderly patients with heart failure after hospitalization.","volume":"160","author":"Abdel-Qadir","year":"2010","journal-title":"Am Heart J"},{"issue":"5","key":"hoi250039r11","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.cardfail.2006.03.006","article-title":"Diuretic use, progressive heart failure, and death in patients in the DIG study.","volume":"12","author":"Domanski","year":"2006","journal-title":"J Card Fail"},{"issue":"3-4","key":"hoi250039r12","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1159\/000047397","article-title":"Diuretic therapy and resistance in congestive heart failure.","volume":"96","author":"Ellison","year":"2001","journal-title":"Cardiology"},{"issue":"14","key":"hoi250039r13","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1016\/j.jacc.2024.02.009","article-title":"Efficacy and safety of dapagliflozin in patients with acute heart failure.","volume":"83","author":"Cox","year":"2024","journal-title":"J Am Coll Cardiol"},{"issue":"16","key":"hoi250039r14","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1056\/NEJMoa2407107","article-title":"Finerenone in heart failure with mildly reduced or preserved ejection fraction.","volume":"391","author":"Solomon","year":"2024","journal-title":"N Engl J Med"},{"issue":"6","key":"hoi250039r15","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1002\/ejhf.3253","article-title":"Finerenone in patients with heart failure with mildly reduced or preserved ejection fraction: rationale and design of the FINEARTS-HF trial.","volume":"26","author":"Vaduganathan","year":"2024","journal-title":"Eur J Heart Fail"},{"issue":"6","key":"hoi250039r16","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1002\/ejhf.3266","article-title":"Baseline characteristics of patients with heart failure with mildly reduced or preserved ejection fraction: the FINEARTS-HF trial.","volume":"26","author":"Solomon","year":"2024","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"hoi250039r17","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1002\/ejhf.2703","article-title":"Sacubitril\/valsartan and loop diuretic requirement in heart failure with preserved ejection fraction in the PARAGON-HF trial.","volume":"25","author":"Chatur","year":"2023","journal-title":"Eur J Heart Fail"},{"issue":"7","key":"hoi250039r18","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1001\/jamacardio.2023.1090","article-title":"Safety and efficacy of empagliflozin and diuretic use in patients with heart failure and preserved ejection fraction: a post hoc analysis of the EMPEROR-Preserved trial.","volume":"8","author":"Butler","year":"2023","journal-title":"JAMA Cardiol"},{"issue":"31","key":"hoi250039r19","doi-asserted-by":"publisher","first-page":"2930","DOI":"10.1093\/eurheartj\/ehad283","article-title":"Dapagliflozin and diuretic utilization in heart failure with mildly reduced or preserved ejection fraction: the DELIVER trial.","volume":"44","author":"Chatur","year":"2023","journal-title":"Eur Heart J"},{"key":"hoi250039r20","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1111\/1467-9868.00259","article-title":"Semiparametric regression for the mean and rate functions of recurrent events.","volume":"62","author":"Lin","year":"2000","journal-title":"J R Stat Soc Series B Stat Methodol"},{"issue":"16","key":"hoi250039r21","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1002\/sim.1815","article-title":"A new approach to modelling interactions between treatment and continuous covariates in clinical trials by using fractional polynomials.","volume":"23","author":"Royston","year":"2004","journal-title":"Stat Med"},{"issue":"3","key":"hoi250039r22","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1002\/ejhf.3179","article-title":"Diuretic use and outcomes in patients with heart failure with reduced ejection fraction: insights from the VICTORIA trial.","volume":"26","author":"Ezekowitz","year":"2024","journal-title":"Eur J Heart Fail"},{"issue":"11","key":"hoi250039r23","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1161\/CIRCULATIONAHA.120.047077","article-title":"Dapagliflozin and diuretic use in patients with heart failure and reduced ejection fraction in DAPA-HF.","volume":"142","author":"Jackson","year":"2020","journal-title":"Circulation"},{"issue":"9689","key":"hoi250039r24","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/S0140-6736(09)61378-7","article-title":"Albuminuria in chronic heart failure: prevalence and prognostic importance.","volume":"374","author":"Jackson","year":"2009","journal-title":"Lancet"},{"issue":"11","key":"hoi250039r25","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.118.005288","article-title":"Prognostic value of albuminuria and influence of spironolactone in heart failure with preserved ejection fraction.","volume":"11","author":"Selvaraj","year":"2018","journal-title":"Circ Heart Fail"},{"issue":"1","key":"hoi250039r26","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1093\/ehjcvp\/pvae074","article-title":"Hypokalaemia in patients with type 2 diabetes and chronic kidney disease: the effect of finerenone-a FIDELITY analysis.","volume":"11","author":"Pitt","year":"2025","journal-title":"Eur Heart J Cardiovasc Pharmacother"}],"container-title":["JAMA Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/articlepdf\/2837458\/jamacardiology_chimura_2025_oi_250039_1758588903.71967.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T15:06:39Z","timestamp":1759935999000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/fullarticle\/2837458"}},"subtitle":["A Prespecified Analysis of the FINEARTS-HF Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2025,10,1]]},"references-count":26,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamacardio.2025.2551","relation":{},"ISSN":["2380-6583"],"issn-type":[{"value":"2380-6583","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10,1]]}}}